NYSEMKT:IBIO iBio (IBIO) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free IBIO Stock Alerts $1.90 +0.12 (+6.74%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$1.75▼$1.9350-Day Range$1.06▼$4.0652-Week Range N/AVolume154,044 shsAverage Volume113,212 shsMarket Capitalization$6.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get iBio alerts: Email Address Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About iBio Stock (NYSEMKT:IBIO)iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Read More IBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBIO Stock News HeadlinesApril 18, 2024 | americanbankingnews.comiBio (NYSEMKT:IBIO) Shares Down 3.6% March 28, 2024 | msn.comiBio, Mesoblast, Kodiak Sciences among healthcare moversApril 24, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 27, 2024 | msn.comMicro-Cap Stock iBio Doubles On Wednesday - Here's WhyMarch 27, 2024 | proactiveinvestors.comiBio partners with AstralBio to develop obesity treatments using AI-driven platformMarch 27, 2024 | marketwatch.comiBio Shares Double After Collaboration Agreement With AstralBioMarch 27, 2024 | investorplace.comWhy Is iBio (IBIO) Stock Up 125% Today?March 27, 2024 | msn.comMega Millions winning numbers for enormous $1.1 billion jackpot on March 26April 24, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 27, 2024 | msn.comRon DeSantis signs bill banning social media for kids under 14 in FloridaMarch 27, 2024 | globenewswire.comiBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic DiseasesMarch 26, 2024 | globenewswire.comiBio Announces $15.0 Million Private PlacementFebruary 26, 2024 | marketwatch.comiBio Sells Preclinical PD-1 Antagonist Antibody Program to OtsukaFebruary 26, 2024 | globenewswire.comiBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to OtsukaFebruary 22, 2024 | money.usnews.comiBio IncFebruary 13, 2024 | msn.comHow to capture screenshots on your Mac: A step-by-step guideFebruary 12, 2024 | msn.comTrain hits, kills person who trespassed on tracks in HaywardFebruary 12, 2024 | msn.comUsher's Wife Responds To Alicia Keys Super Bowl DramaJanuary 16, 2024 | finance.yahoo.comiBio Announces Participation in 23rd Annual PepTalk ConferenceDecember 26, 2023 | finance.yahoo.comiBio Amends and Extends Maturity of Credit AgreementDecember 8, 2023 | benzinga.comLooking Into iBio's Recent Short InterestDecember 5, 2023 | marketwatch.comIBio Shares Drop 43% After Public OfferingDecember 5, 2023 | msn.comiBio prices 2.25M shares at $2.00 in public offeringDecember 5, 2023 | markets.businessinsider.comIBio Prices Public Offering Of 2.25 Mln Shares At $2/shrDecember 5, 2023 | finance.yahoo.comiBio, Inc. Announces Pricing of $4.5 Million Public OfferingNovember 28, 2023 | benzinga.comiBio Stock (AMEX:IBIO) Dividends: History, Yield and DatesNovember 28, 2023 | finanznachrichten.deiBio, Inc.: iBio Announces Reverse Stock SplitSee More Headlines Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/24/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEMKT:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone(302) 355-0650Fax302-356-1173Employees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,010,000.00 Net MarginsN/A Pretax Margin-41,546.00% Return on Equity-150.59% Return on Assets-52.83% Debt Debt-to-Equity Ratio0.04 Current Ratio0.91 Quick Ratio0.91 Sales & Book Value Annual Sales$50,000.00 Price / Sales132.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book0.72Miscellaneous Outstanding Shares3,484,000Free Float3,445,000Market Cap$6.62 million OptionableN/A Beta-3.51 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Martin B. Brenner D.V.M. (Age 53)Ph.D., CEO & Chief Scientific Officer Comp: $577.31kMr. Felipe Duran (Age 44)Chief Financial Officer Comp: $1.07MStephen KilmerInvestor Relations OfficerMr. Marc Banjak J.D.General CounselMr. Robert B. Kay (Age 84)Interim Secretary & Interim Treasurer Comp: $92.69kKey CompetitorsTherapix BiosciencesOTCMKTS:TRPXYEmmaus Life SciencesOTCMKTS:EMMATenax TherapeuticsNASDAQ:TENXProcessa PharmaceuticalsNASDAQ:PCSABioRestorative TherapiesOTCMKTS:BRTXView All CompetitorsInsidersMartin BrennerSold 210 sharesTotal: $1,302.00 ($6.20/share)Martin BrennerSold 250 sharesTotal: $1,550.00 ($6.20/share)Martin BrennerSold 225 sharesTotal: $2,295.00 ($10.20/share)Martin BrennerSold 2,351 sharesTotal: $27,741.80 ($11.80/share)Martin BrennerSold 209 sharesTotal: $2,842.40 ($13.60/share)View All Insider Transactions IBIO Stock Analysis - Frequently Asked Questions How have IBIO shares performed in 2024? iBio's stock was trading at $1.37 on January 1st, 2024. Since then, IBIO stock has increased by 38.7% and is now trading at $1.90. View the best growth stocks for 2024 here. How were iBio's earnings last quarter? iBio, Inc. (NYSEMKT:IBIO) issued its quarterly earnings data on Monday, November, 15th. The company reported ($20.00) earnings per share for the quarter, beating analysts' consensus estimates of ($25.00) by $5.00. The business had revenue of $0.21 million for the quarter. When did iBio's stock split? iBio's stock reverse split on the morning of Wednesday, November 29th 2023. The 1-20 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEMKT:IBIO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.